"NAD" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Descriptor ID |
D009243
|
MeSH Number(s) |
D03.633.100.759.646.138.694 D08.211.589 D13.695.667.138.694 D13.695.827.068.694
|
Concept/Terms |
NAD- NAD
- Dihydronicotinamide Adenine Dinucleotide
- Adenine Dinucleotide, Dihydronicotinamide
- Dinucleotide, Dihydronicotinamide Adenine
- Diphosphopyridine Nucleotide
- Nucleotide, Diphosphopyridine
- Nadide
- Nicotinamide-Adenine Dinucleotide
- Dinucleotide, Nicotinamide-Adenine
- Nicotinamide Adenine Dinucleotide
- Coenzyme I
- DPN
|
Below are MeSH descriptors whose meaning is more general than "NAD".
Below are MeSH descriptors whose meaning is more specific than "NAD".
This graph shows the total number of publications written about "NAD" by people in this website by year, and whether "NAD" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2005 | 1 | 1 | 2 |
2006 | 1 | 1 | 2 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 2 | 0 | 2 |
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 0 | 4 | 4 |
2017 | 0 | 1 | 1 |
2019 | 2 | 0 | 2 |
2020 | 0 | 2 | 2 |
2021 | 0 | 2 | 2 |
2022 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "NAD" by people in Profiles.
-
NADH-bound AIF activates the mitochondrial CHCHD4/MIA40 chaperone by a substrate-mimicry mechanism. EMBO J. 2025 Feb; 44(4):1220-1248.
-
Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024 Sep; 633(8031):923-931.
-
Enhanced Succinate Oxidation with Mitochondrial Complex II Reactive Oxygen Species Generation in Human Prostate Cancer. Int J Mol Sci. 2022 Oct 12; 23(20).
-
Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife. 2022 07 11; 11.
-
The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022 05 10; 39(6):110792.
-
NAXE deficiency: A neurometabolic disorder of NAD(P)HX repair amenable for metabolic correction. Mol Genet Metab. 2022 06; 136(2):101-110.
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
-
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2022 02 01; 24(2):229-244.
-
Nuclear NAD+ homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv. 2021 07; 7(30).
-
Molecular dynamics, residue network analysis, and cross-correlation matrix to characterize the deleterious missense mutations in GALE causing galactosemia III. Cell Biochem Biophys. 2021 Jun; 79(2):201-219.